Obeldesivir

obeldesivir is an oral antiviral being tested as post-exposure prophylaxis in the first authorised therapeutic trial for Bundibugyo ebolavirus. Dosing began on 2 July 2026, when WHO enrolled the first patient in the randomised trial in Ituri Province, with obeldesivir assigned as a separate post-exposure-prophylaxis Arm for people who have been exposed to a confirmed Bundibugyo patient but have not yet developed symptoms. WHO Disease Outbreak News 607 had noted that obeldesivir differs from the drugs named in the 28 May expert advisory, making it a notable change to the originally-anticipated treatment protocol.

Chemically, obeldesivir is a prodrug: an inactive compound the body converts into GS-441524, a nucleoside analogue that the virus cannot easily replicate around. GS-441524 is the parent nucleoside of remdesivir, the intravenous antiviral that was evaluated but not prioritised in earlier stages of the trial design. The oral route matters in a conflict-zone outbreak: post-exposure prophylaxis taken as a tablet is FAR easier to administer in field conditions than an intravenous drip, and extends coverage to contacts who cannot reach a treatment centre.

obeldesivir is investigational and not approved for any indication. By mid-July 2026, roughly 60 patients had enrolled across the trial's three arms, with results expected around September or October per Africa CDC; no efficacy data has yet been published. Its significance here is practical: it provides a prophylactic option for healthcare workers and confirmed contacts in a setting where the virus kills and no licensed Bundibugyo countermeasure exists.